Abstract
Hepatocellular carcinoma (HCC) is a typical hypervascular tumor. Many angiogenic factors have been studied in HCC, and several anti-angiogenic therapies have been tested in animal models and patients. This paper summarizes the latest findings, especially regarding the clinical significance of endothelial cell markers and angiogenic factors in HCC, and experimental and clinical anti-angiogenesis therapies. Further developments in this area, such as endothelial cell-oriented research and better experimental and clinical designs in the evaluation of anti-angiogenic therapies are discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inducing Agents / metabolism*
-
Angiogenesis Inhibitors / therapeutic use*
-
Angiopoietins / metabolism
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Hepatocellular / blood supply*
-
Carcinoma, Hepatocellular / drug therapy
-
Chemotherapy, Adjuvant
-
Clinical Trials as Topic
-
Cyclohexanes
-
Endostatins / metabolism
-
Fibroblast Growth Factor 2 / metabolism
-
Humans
-
Interferons / pharmacology
-
Interleukin-8 / metabolism
-
Liver Neoplasms / blood supply*
-
Liver Neoplasms / drug therapy
-
Neovascularization, Pathologic / drug therapy*
-
Neovascularization, Pathologic / metabolism*
-
O-(Chloroacetylcarbamoyl)fumagillol
-
Radiotherapy, Adjuvant
-
Research Design
-
Sesquiterpenes / pharmacology
-
Somatostatin / pharmacology
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Angiogenesis Inducing Agents
-
Angiogenesis Inhibitors
-
Angiopoietins
-
Antineoplastic Agents
-
Cyclohexanes
-
Endostatins
-
Interleukin-8
-
Sesquiterpenes
-
Vascular Endothelial Growth Factor A
-
Fibroblast Growth Factor 2
-
Somatostatin
-
Interferons
-
O-(Chloroacetylcarbamoyl)fumagillol